Table 59Summary of included studies. Comparison 58. Augmenting with thyroid hormone versus continuing with antidepressant (+/− placebo)

StudyPopulationInterventionComparisonDetails of inadequate response/treatment resistanceComments

Fang 2011

RCT

China

N=93

Mean age (years): NR

Gender (% female): NR

Ethnicity (% BME): NR

Baseline severity: NR (more severe)

Thyroid hormone 80mg/day + paroxetineParoxetine 20mg/dayTRD: Inadequate response to ≥2 adequate treatments from different classes of antidepressants in the current depressive episode (adequate dosages of antidepressants with ≥3-month duration) determined through medical records and/or prospective treatment. Paroxetine 1-week lead-in

Treatment length (weeks): 8

Outcomes:

  • Remission
  • Response
  • Quality of life physical component score
  • Quality of life mental component score

Joffe 1993

RCT

Canada

N=33

Mean age (years): NR

Gender (% female): 67

Ethnicity (% BME): NR

Baseline severity: HAMD 18.75 (more severe)

Liothyronine sodium (triiodothyronine, T3) 37.5μg + desipramine/imipraminePlacebo + desipramine/imipramineInadequate response (HAMD≥16) to a previous adequate trial of desipramine hydrochloride (90%) or imipramine hydrochloride (10%) ≥5 weeks

Treatment length (weeks): 2

Outcomes:

  • Depression symptomatology endpoint
  • Depression symptomatology change score
  • Remission
  • Discontinuation due to any reason
  • Discontinuation due to side effects

BME: black and minority ethnic; HAMD: Hamilton depression scale; NR: not reported; RCT: randomised controlled trial; TRD: treatment-resistant depression

From: Further-line treatment

Cover of Further-line treatment
Further-line treatment: Depression in adults: Evidence review D.
NICE Guideline, No. 222.
Copyright © NICE 2022.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.